The importance of this pathway in fibrosis is supported by clinical trials in which drugs such as GLPG1690 (an ATX inhibitor) and BMS986020 (an LPA1 receptor antagonist) attenuated the progression of IPF [144,145]. This evidence concerns the gene ENPP2 and idiopathic pulmonary fibrosis.